Elron Ventures Ltd · TASE:ELRN
Elron Ventures — Investor Presentation (August 2019)
21 slides from Elron Ventures's investor presentation, August 2019
Slide 1: Elron - Investor Presentation August 2019
ELRON - INVESTOR PRESENTATION August 2019
Slide 2: Comments
This presentation is for information purposes only. By this presentation, Elron does not intend to solicit offers to purchase its securities and the presentation does not constitute an invitation to receive such offers, and nothing said therein constitutes a COMMENTS “public offering”, as defined in
Slide 3: Building Value in Venture Capital Investments
BUILDING VALUE IN VENTURE CAPITAL INVESTMENTS 1960s Defense Elbit 10 exits totaling $1.5b, Long-standing focus in 1970s including proceeds in excess of the medical device field Medical Imaging $500m for Elron and RDC Elscint 1980s Semiconductors Orbotech | Zoran Experienced team Successful entry 199
Slide 4: Building Value in Venture Capital Investments
BUILDING MEDICAL DEVICES CYBER/IT Elron’s field of focus in the Developing the field for VALUE IN last decade the next decade VENTURE CAPITAL BALANCED MATURITY BETWEEN INITIAL R&D NEW VERTICAL IN THE LAST 3 YEARS INVESTMENTS STAGE START-UPS THROUGH COMPANIES IN ADVANCED STAGES Current ~$155m Current
Slide 5: Teamwork
TEAMWORK An experienced team which led 10 exits, dozens of investments, and follow-on financings totaling hundreds of millions of $s over the last decade ARI BRONSHTEIN YARON ELAD ZVIKA SLOVIN ZOHAR ROZENBERG CEO CFO VP Medical Devices VP Cyber Investments Extensive experience in Extensive finance e
Slide 6: Exits at a Value of $1.5B
EXITS AT A VALUE OF $1.5B Our share in proceeds $550M Acquired by COVIDIEN Sold to ROCHE Sold to PALO ALTO Sold to Sold to Sold to NETWORKS ENABLENCE WAVE Sold to Sold to Sold to BRUKER MICROSOFT SYSTEMS Sold to CORP ALVARION VOLCANO ZOLL May June Sept. Nov. Nov. Feb. Sept. Oct. July Apr. 2010 2010
Slide 7: At the Pivot of Our Activity
AT THE PIVOT OF OUR ACTIVITY CARTIHEAL BRAINSGATE OPENLEGACY Implant for cartilage and bone Electrical stimulation-based treatment Automated API integration platform regeneration in load-bearing joints for ischemic stroke that speeds digital transformation $17m $29m $8.2m Total (29%) Total (30%) Tot
Slide 8: Cartilage & Bone Regeneration in Joints Such as the Knee
CARTILAGE & BONE REGENERATION IN JOINTS SUCH AS THE KNEE Cartilage injuries affect millions of patients worldwide. The need for a simple, fast, and off-the shelf solution to restore cartilage is an unmet challenge facing medicine today. >400 patients were In Sep. 2017 a pivotal clinical trial was tr
Slide 9: Electrical Stimulation-Based Treatment for Ischemic Stroke
ELECTRICAL STIMULATION-BASED TREATMENT FOR ISCHEMIC STROKE The annual number of new ischemic strokes in the USA is approximately 700,000. The current treatment for stroke is very limited. In Mar. 2018 the company completed the largest The FDA trial results stroke trial ever done: 1,000 patients, tre
Slide 10: BrainsGate's FDA Trial Results
BRAINSGATE’S FDA TRIAL RESULTS ImpACT-24B: SPG stimulation started within 24 hours reduced disability in a broad category of cortical stroke patients (50% of the trial population) PROFILE The longest clinically tested treatment window – on average, patients were treated 19 hrs after stroke onset Per
Slide 11: OpenLegacy: From Legacy System to Application in Record Speed
PARTNERS: FROM LEGACY SYSTEM TO APPLICATION IN RECORD SPEED Raised $30m in financing round Team of 100 employees, from leading strategic investors in 8 locations worldwide The co’s first multi-million-$ Over 20 customers transaction with a global banking worldwide, including 1st-tier customer (money
Slide 12: Cyber/IT
ELRON CYBER/IT @
Slide 13: The Next Decade: Cyber & IT
THE NEXT DECADE: CYBER & IT LEADERSHIP RAFAEL INVESTMENT ZOHAR ROZENBERG RAFAEL (through RDC, VP Cyber Investments a joint venture) Over 20 years of experience; Vast experience in previously Head of the IDF's technological projects, Cyber Department; joined extensive knowledge in the Elron in 2016 a
Slide 14: Cyber & IT – Growth Catalyst in the Next Decade
Exit Exit CYBER & IT – GROWTH CATALYST IN THE NEXT DECADE Seed Round A Round B 14
Slide 15: Top Headlines on Our Cyber/IT Companies
TOP HEADLINES ON OUR CYBER/IT COMPANIES 15
Slide 16: Investment Partners
SAMSUNG NE>:T * CE VENTURES INVESTMENT PARTNERS A accelmed VIOLA VENTURES ELRON CARDIF Ba | Leumi Partners ON O.G. TECH VENTURES 119 techwald INVESTING IN LIFECARE Ekkamet AEMnaImn ACCELERATING CURE TH PRYTEK Enterprise Software g Investors COMMERZBANK (9 arvato BERTELSMANN *mtp Capital @Bbioventus
Slide 17: ~$190M Invested in Companies, ~$55M Liquidity Balance
~$190M Holdings in companies 1 Book value at Our holdings based on valuation of last June 30, 2019 ($m) INVESTED IN financing round 2 ($m) COMPANIES, Medical: BrainsGate (27%) 1.4 ~$55M CartiHeal (27%) 2.4 LIQUIDITY Pocared (55%) 8.6 35.8 BALANCE, Other medical companies 11.0 19.9 ~$65 MARKET Total
Slide 18: Summary
~$245M EXPERIENCED TEAM Total cash balance & investments leading the company over the last decade in existing companies 10 EXITS MATURE PORTFOLIO OF COMPANIES SUMMARY in recent years IN THE NEXT YEAR INVESTMENT OPPORTUNITY IN A Value-building events in PUBLIC COMPANY IN THE VC SPACE, pivotal compani
Slide 19: Thank You
THANK YOU. elron.com
Slide 20: Our Medical Device Companies
CARTIHEAL BRAINSGATE POCARED Implant for Electrical Rapid and cartilage and stimulation- automated 71% OUR bone 29% based 30% microbiology by Elron & RDC regeneration treatment laboratory MEDICAL in load- for ischemic system DEVICE bearing Our investment: $17m stroke Our investment: $29m Our investm
Slide 21: Our Cyber/IT Companies
OPENLEGACY ALCIDE OUR CYBER/IT Automated API Universal security COMPANIES integration platform that 29% by RDC and management platform for 26% speeds digital hybrid data transformation Our investment: centers Our investment: $8.2m $3.9m SIXGILL SECUREDTOUCH IRONSCALES CYNERIO Cyber Behavioral Automa